文献速递其他结缔组织病

空间频域成像评估系统性硬化症皮肤纤维化的前瞻性队列研究

Spatial frequency domain imaging for assessment of skin fibrosis in systemic sclerosis: a prospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2026-10-14

这项单中心前瞻性队列研究纳入49例系统性硬化症患者和25名对照,评估空间频域成像(SFDI)参数与改良Rodnan皮肤评分(mRSS)及组织学纤维化的关联。结果显示,SFDI参数在系统性硬化症患者中显著降低,与局部mRSS及组织学纤维化呈弱至中度相关,提示SFDI可作为客观、无创的皮肤结局指标。

要点

  • SFDI参数在系统性硬化症患者所有mRSS分层中均显著低于对照,包括mRSS为0的部位。
  • 局部mRSS每增加1分,Rd和μs'均显著下降,提示SFDI可量化皮肤受累。

核心结论

  • SFDI可提供客观、无创的系统性硬化症皮肤受累测量,与临床、影像和组织学评估一致,支持其作为定量结局指标的潜力。

研究设计与样本

  • 单中心前瞻性队列研究,于波士顿医疗中心风湿科开展,纳入49例系统性硬化症患者和25名健康对照进行最终分析,其中34例患者和16名对照获取活检样本。

主要发现

  • 系统性硬化症队列的Rd和μs'在所有mRSS分层中均显著低于对照队列,包括mRSS为0的部位。

关键数值与推荐

  • 系统性硬化症患者符合2013年美国风湿病学会-欧洲抗风湿病联盟分类标准,年龄≥18岁;对照为无自身免疫病或已知皮肤病理的年龄≥18岁人群。

临床怎么用

  • SFDI或可作为系统性硬化症皮肤病变的定量结局指标,用于多中心试验中评估皮肤疾病,但需进一步验证。

局限性

  • 单中心研究,样本量有限,最终分析仅49例患者和25名对照,需多中心更大样本验证。
  • 有系统性硬化症亲身经历者未参与研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic sclerosis is an autoimmune disease with no approved skin-directed therapies. The modified Rodnan skin score (mRSS) is the standard measure of skin involvement in systemic sclerosis, but it has limitations. There is an unmet need for a non-invasive skin outcome measure that is objective, biologically anchored to dermal fibrosis, and scalable for multicentre trials. We evaluated spatial frequency domain imaging (SFDI), a wide field, non-contact optical method as a systemic sclerosis skin outcome measure. METHODS: This single-centre, prospective, cohort study was done at the Division of Rheumatology at the Boston Medical Center (Boston, MA, USA). Eligible patients were aged 18 years or older with systemic sclerosis fulfilling the 2013 American College of Rheumatology-European League Against Rheumatism classification criteria. Control participants were people aged 18 years or older without autoimmune disease or known skin pathology. For all participants, exclusion criteria included skin malignancy, wounds or rashes at SFDI measurement sites (dorsal hands, forearms, and fingers). Participants in the pilot phase completed one study visit with SFDI, mRSS assessment, and optional forearm biopsy. In the expanded protocol phase, participants had a baseline visit, with follow-up visits once every 3 months during the first year and once every 6 months thereafter for 3 years. At each study visit, SFDI, high-frequency ultrasound, and durometry were done in all participants, and mRSS was assessed in patients with systemic sclerosis. Optional forearm biopsy and blood collection was done at baseline in consenting participants. Main analyses assessed baseline associations of SFDI parameters (diffuse reflectance [Rd] and reduced scattering coefficient [μs']) with mRSS and correlations with histological features of skin involvement in forearm biopsies (dermal fibrosis, collagen content, myofibroblast staining, epidermal and dermal thickness, and additional histological features). Linear mixed-effects models were used for associations and Spearman models for correlations. People with lived experience of systemic sclerosis were not involved in the study design. FINDINGS: Between Oct 17, 2019, and June 18, 2025, 54 patients with systemic sclerosis and 30 healthy control participants were enrolled across the pilot and expanded protocol phases. The final analysis included 49 participants with systemic sclerosis and 25 control participants; biopsy samples were obtained from 34 participants with systemic sclerosis and 16 control participants. 38 (78%) of 49 participants with systemic sclerosis were female, 11 (22%) were male, 34 (69%) were White, and mean age was 50 years (SD 16). 20 (80%) of 25 control participants were female, five (20%) were male, 14 (56%) were White, and mean age was 49 years (SD 14). Rd and μs' were significantly lower in the systemic sclerosis cohort than in the control cohort across all mRSS strata, including sites where mRSS was 0. For each one-point increase in local mRSS there was a decrease in Rd (β=-0·0028, 95% CI -0·0050 to -0·0006; p=0·014) and μs' (β=-0·0158, 95% CI -0·0314 to -0·0003; p=0·047). SFDI correlations were weak to moderate with mRSS (r ranged from -0·38 to -0·48) and moderate with histological fibrosis (r ranged from -0·34 to -0·52). INTERPRETATION: SFDI provides an objective, non-invasive measure of skin involvement in systemic sclerosis that aligns with established clinical, imaging, and histological assessments. These findings support its potential as a quantitative outcome measure for evaluating skin disease in systemic sclerosis, consistent with Outcome Measures in Rheumatology principles. FUNDING: National Institutes of Health, National Scleroderma Foundation, Scleroderma Clinical Trials Consortium.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Vo H, Mehendale AM, Azzam M, et al. Spatial frequency domain imaging for assessment of skin fibrosis in systemic sclerosis: a prospective cohort study. Lancet Rheumatol. 2026. PMID: 42874627. doi:10.1016/S2665-9913(26)00229-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。